Conference Proceedings

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) Patients: An Update of Overall Survival in Castor

Suzanne Lentzsch, Hang Quach, Asher A Chanan-Khan, Noemi Horvath, Marcelo Capra, Roberto Ovilla, Jae-Cheol Jo, Ho-Jin Shin, Piruntha Thiyagarajah, Himal Amin, Tineke Casneuf, Pieter Sonneveld, Jordan Schecter, Vania TM Hungria

BLOOD | AMER SOC HEMATOLOGY | Published : 2017

University of Melbourne Researchers

Grants

Funding Acknowledgements

Lentzsch: British-Myers Squibb, Celgene, Janssen: Consultancy; Takeda: Speakers Bureau; Caelum BioSciences: Equity Ownership. Quach: Janssen: Consultancy, Honoraria; Celgene:Consultancy, Honoraria, Research Funding; Amgen: Consultancy, Honoraria, Research Funding; Takeda: Consultancy, Honoraria. Capra: Janssen: Speakers Bureau. Ovilla: Takeda Pharmaceutical Company: Consultancy, Honoraria. Thiyagarajah: Janssen: Employment. Amin: Janssen: Employment. Casneuf: Janssen:Employment. Sonneveld: Celgene Corporation, Amgen, Janssen, Karyopharm, PharmaMar, SkylineDx: Honoraria; Celgene Corporation, Amgen, Janssen, Karyopharm, SkylineDx, PharmaMar: Consultancy; Celgene, Amgen, Janssen, Karyopharm, Takeda: Consultancy, Honoraria, Research Funding. Schecter: Janssen:Employment. Hungria: Celgene, Roche, Takeda, Janssen, Amgen: Honoraria.